Michael V. Seiden

Medicine · Health Sciences

56h-index14.0kcitations241works1.32yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(85), Cancer Genomics and Diagnostics(45), Intraperitoneal and Appendiceal Malignancies(20), Endometrial and Cervical Cancer Treatments(19), Cancer Treatment and Pharmacology(17)

Publications237 total

Prognostic significance of blood-based multi-cancer detection in circulating tumor DNA (ctDNA): 5-year outcomes analysis.
Journal of Clinical Oncology·2025
Abstract 3895: Prognostic significance of blood-based multi-cancer detection in cell-free DNA: 4-year outcomes analysis
Cancer Research·2024· 1 cited
Health State Utilities Associated with False-Positive Cancer Screening Results
PharmacoEconomics - Open·2024· 3 citedOpen Access
Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers
JCO Precision Oncology·2023· 13 citedOpen Access
Supplementary Figures from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
2023Open Access
Supplementary Figures 1 - 2, Table 1 from Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
2023Open Access
Data from Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
2023Open Access
Data from Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
2023Open Access
Supplementary Table 3 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
2023Open Access
Supplementary Table 1 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
2023Open Access
Supplementary Table 1 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
2023Open Access
Supplementary Figures from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
2023Open Access
Data from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
2023Open Access
Supplementary Figures 1 - 2, Table 1 from Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
2023Open Access
Supplementary Table 2 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
2023Open Access
Supplementary Table 3 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
2023Open Access
Supplementary Table 2 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
2023Open Access
Data from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
2023Open Access
The Promise of Multicancer Early Detection
The American Journal of Medicine·2023· 1 citedOpen Access
Evaluation of cell-free DNA approaches for multi-cancer early detection
Cancer Cell·2022· 284 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Zhenfeng Duan(14), Richard T. Penson(11), Rosemary Foster(6), Diana E. Lamendola(6), Ursula A. Matulonis(6), Eric A. Klein(5), Charles Swanton(4), David P. Ryan(4), George D. Demetri(4), Mansoor M. Amiji(4), Arlan F. Fuller(4), Annekathryn Goodman(4), Jeffrey G. Supko(4), Rushdia Z. Yusuf(4), Geoffrey R. Oxnard(3), Minetta C. Liu(3), Allen Lee Cohn(3), Dong Zhao(3), Eric T. Fung(3), Earl Hubbell(3)